Literature DB >> 12114223

Diabetic nephropathy.

J N Harvey.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12114223      PMCID： PMC1123624          DOI： 10.1136/bmj.325.7355.59

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Prediction of albumin excretion rate from albumin-to-creatinine ratio.

Authors:  J N Harvey; K Hood; J K Platts; S Devarajoo; P A Meadows
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

2.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

3.  Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes.

Authors:  J N Harvey; K Rizvi; L Craney; J Messenger; R Shah; P A Meadows
Journal:  Diabet Med       Date:  2001-12       Impact factor: 4.359

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

10.  Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group.

Authors: 
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122
  10 in total
  4 in total

1.  Effect of glycaemic control on glomerular filtration rate in diabetes mellitus patients.

Authors:  Allen Meeme; Hannington Kasozi
Journal:  Afr Health Sci       Date:  2009-08-01       Impact factor: 0.927

2.  Low-protein vegetarian diet with alpha-chetoanalogues prior to pre-emptive pancreas-kidney transplantation.

Authors:  Giorgina B Piccoli; Daria Motta; Guido Martina; Valentina Consiglio; Massimo Gai; Elisabetta Mezza; Emanuela Maddalena; Manuel Burdese; Loredana Colla; Fabio Tattoli; Patrizia Anania; Maura Rossetti; Giorgio Soragna; Giorgio Grassi; Franco Dani; Alberto Jeantet; Giuseppe P Segoloni
Journal:  Rev Diabet Stud       Date:  2004-08-10

Review 3.  Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure.

Authors:  Dean M Robinson; Monique P Curran; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  High glucose downregulates myocardin expression in rat glomerular mesangial cells via the ERK signaling pathway.

Authors:  Ming Li; Lijuan Xu; Guowei Feng; Yan Zhang; Xin Wang; Yuebing Wang
Journal:  Oncotarget       Date:  2017-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.